The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has approved decitabine for the treatment of acute myeloid leukemia. According to the approved indication: "decitabine (Dacogen) is indicated for the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy." While side effects reported include nausea, diarrhea, and possibly pneumonia and anemia, the benefits of using decitabine do show an increase in overall survival.
To read more about this study, click here.
No comments:
Post a Comment